Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first. Monday, the Indianapolis drugmaker trumpeted phase 3 data showing its IL ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback